Finotonlimab is a highly specialized recombinant humanized monoclonal antibody of the immunoglobulin G4 isotype target the human programmed cell death protein 1 receptor with exceptional binding affinity and selectivity, restoration of T-lymphocyte mediated anti-tumor immunity by disrupting the inhibitory signaling axis established through interactions with PD-L1 and PD-L2 ligands across various preclinical and clinical experimental models of advanced solid malignancies.